cell therapy catapult limited
cell therapy catapult limited Company Information
Company Number
07964711
Next Accounts
Dec 2025
Shareholders
-
Group Structure
View All
Industry
Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
Registered Address
12th floor tower wing b, guys hospital, london, SE1 9RT
Website
ct.catapult.org.ukcell therapy catapult limited Estimated Valuation
Pomanda estimates the enterprise value of CELL THERAPY CATAPULT LIMITED at £114.3m based on a Turnover of £53.5m and 2.14x industry multiple (adjusted for size and gross margin).
cell therapy catapult limited Estimated Valuation
Pomanda estimates the enterprise value of CELL THERAPY CATAPULT LIMITED at £63.9m based on an EBITDA of £4.2m and a 15.34x industry multiple (adjusted for size and gross margin).
cell therapy catapult limited Estimated Valuation
Pomanda estimates the enterprise value of CELL THERAPY CATAPULT LIMITED at £170.3m based on Net Assets of £74.2m and 2.3x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Cell Therapy Catapult Limited Overview
Cell Therapy Catapult Limited is a live company located in london, SE1 9RT with a Companies House number of 07964711. It operates in the other professional, scientific and technical activities n.e.c. sector, SIC Code 74909. Founded in February 2012, it's largest shareholder is unknown. Cell Therapy Catapult Limited is a established, large sized company, Pomanda has estimated its turnover at £53.5m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Cell Therapy Catapult Limited Health Check
Pomanda's financial health check has awarded Cell Therapy Catapult Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 4 areas for improvement. Company Health Check FAQs
7 Strong
1 Regular
4 Weak
Size
annual sales of £53.5m, make it larger than the average company (£1.7m)
£53.5m - Cell Therapy Catapult Limited
£1.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 6%, show it is growing at a slower rate (8.6%)
6% - Cell Therapy Catapult Limited
8.6% - Industry AVG
Production
with a gross margin of 98.5%, this company has a lower cost of product (46%)
98.5% - Cell Therapy Catapult Limited
46% - Industry AVG
Profitability
an operating margin of -13.3% make it less profitable than the average company (5.5%)
-13.3% - Cell Therapy Catapult Limited
5.5% - Industry AVG
Employees
with 406 employees, this is above the industry average (17)
406 - Cell Therapy Catapult Limited
17 - Industry AVG
Pay Structure
on an average salary of £70.2k, the company has a higher pay structure (£48.3k)
£70.2k - Cell Therapy Catapult Limited
£48.3k - Industry AVG
Efficiency
resulting in sales per employee of £131.8k, this is more efficient (£111.5k)
£131.8k - Cell Therapy Catapult Limited
£111.5k - Industry AVG
Debtor Days
it gets paid by customers after 61 days, this is near the average (54 days)
61 days - Cell Therapy Catapult Limited
54 days - Industry AVG
Creditor Days
its suppliers are paid after 2063 days, this is slower than average (32 days)
2063 days - Cell Therapy Catapult Limited
32 days - Industry AVG
Stock Days
it holds stock equivalent to 1124 days, this is more than average (30 days)
1124 days - Cell Therapy Catapult Limited
30 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 80 weeks, this is more cash available to meet short term requirements (29 weeks)
80 weeks - Cell Therapy Catapult Limited
29 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 45.3%, this is a lower level of debt than the average (51.5%)
45.3% - Cell Therapy Catapult Limited
51.5% - Industry AVG
CELL THERAPY CATAPULT LIMITED financials
Cell Therapy Catapult Limited's latest turnover from March 2024 is £53.5 million and the company has net assets of £74.2 million. According to their latest financial statements, Cell Therapy Catapult Limited has 406 employees and maintains cash reserves of £35.8 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 53,525,000 | 59,114,000 | 59,946,000 | 44,529,000 | 31,539,000 | 26,823,000 | 21,065,000 | 18,025,000 | 16,458,000 | 15,447,000 | 16,681,000 | 1,976,770 |
| Other Income Or Grants | ||||||||||||
| Cost Of Sales | 779,000 | 1,420,000 | 1,914,000 | 1,573,000 | 2,051,000 | |||||||
| Gross Profit | 52,746,000 | 57,694,000 | 58,032,000 | 42,956,000 | 29,488,000 | |||||||
| Admin Expenses | 59,873,000 | 54,210,000 | 44,150,000 | 17,524,000 | 23,544,000 | |||||||
| Operating Profit | -7,127,000 | 3,484,000 | 13,882,000 | 25,432,000 | 5,944,000 | 8,910,000 | 5,444,000 | 24,041,000 | 8,031,000 | 665,000 | 8,705,000 | 266,565 |
| Interest Payable | 37,000 | 48,000 | 28,000 | 21,000 | 85,000 | 78,000 | 88,000 | 119,000 | 108,000 | |||
| Interest Receivable | 667,000 | 54,000 | 43,000 | 26,000 | 39,000 | 29,000 | 22,000 | 15,000 | 15,000 | 18,000 | ||
| Pre-Tax Profit | -6,497,000 | 3,490,000 | 13,897,000 | 25,437,000 | 5,898,000 | 8,852,000 | 6,010,000 | 23,918,000 | 7,957,000 | 683,000 | 8,705,000 | 266,565 |
| Tax | -312,000 | -1,154,000 | -7,432,000 | -4,764,000 | -1,568,000 | -1,035,000 | -1,105,000 | -3,790,000 | -1,291,000 | -147,000 | -1,752,000 | -62,223 |
| Profit After Tax | -6,809,000 | 2,336,000 | 6,465,000 | 20,673,000 | 4,330,000 | 7,817,000 | 4,905,000 | 20,128,000 | 6,666,000 | 536,000 | 6,953,000 | 204,342 |
| Dividends Paid | ||||||||||||
| Retained Profit | -6,809,000 | 2,336,000 | 6,465,000 | 20,673,000 | 4,330,000 | 7,817,000 | 4,905,000 | 20,128,000 | 6,666,000 | 536,000 | 6,953,000 | 204,342 |
| Employee Costs | 28,512,000 | 27,597,000 | 26,237,000 | 19,482,000 | 13,780,000 | 11,936,000 | 10,082,000 | 8,757,000 | 7,443,000 | 5,762,000 | 3,376,000 | 490,663 |
| Number Of Employees | 406 | 407 | 403 | 337 | 213 | 185 | 150 | 128 | 110 | 83 | 49 | 5 |
| EBITDA* | 4,167,000 | 12,935,000 | 21,708,000 | 32,241,000 | 10,540,000 | 13,256,000 | 7,612,000 | 25,909,000 | 9,648,000 | 1,975,000 | 8,721,000 | 270,305 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 74,657,000 | 81,038,000 | 79,552,000 | 71,916,000 | 55,402,000 | 52,384,000 | 44,244,000 | 40,019,000 | 16,448,000 | 9,592,000 | 8,924,000 | 248,220 |
| Intangible Assets | 160,000 | 1,479,000 | 2,257,000 | 2,695,000 | 935,000 | 773,000 | 97,000 | |||||
| Investments & Other | 150,000 | |||||||||||
| Debtors (Due After 1 year) | ||||||||||||
| Total Fixed Assets | 74,967,000 | 82,517,000 | 81,809,000 | 74,611,000 | 56,337,000 | 53,157,000 | 44,341,000 | 40,019,000 | 16,448,000 | 9,592,000 | 8,924,000 | 248,220 |
| Stock & work in progress | 2,400,000 | 1,308,000 | 61,000 | 55,000 | 52,000 | 66,000 | 107,000 | |||||
| Trade Debtors | 8,968,000 | 12,905,000 | 15,914,000 | 5,300,000 | 6,749,000 | 2,867,000 | 2,912,000 | 1,138,000 | 655,000 | 254,000 | 55,000 | 835,465 |
| Group Debtors | ||||||||||||
| Misc Debtors | 13,496,000 | 12,591,000 | 10,784,000 | 12,665,000 | 7,141,000 | 10,228,000 | 11,891,000 | 13,498,000 | 13,493,000 | 7,202,000 | 7,215,000 | 2,233,796 |
| Cash | 35,755,000 | 34,204,000 | 33,702,000 | 29,071,000 | 11,519,000 | 11,337,000 | 9,378,000 | 7,122,000 | 5,956,000 | 3,647,000 | 4,769,000 | 392,646 |
| misc current assets | 44,000 | |||||||||||
| total current assets | 60,619,000 | 61,008,000 | 60,461,000 | 47,091,000 | 25,409,000 | 24,432,000 | 24,181,000 | 21,810,000 | 20,170,000 | 11,210,000 | 12,083,000 | 3,461,907 |
| total assets | 135,586,000 | 143,525,000 | 142,270,000 | 121,702,000 | 81,746,000 | 77,589,000 | 68,522,000 | 61,829,000 | 36,618,000 | 20,802,000 | 21,007,000 | 3,710,127 |
| Bank overdraft | ||||||||||||
| Bank loan | ||||||||||||
| Trade Creditors | 4,404,000 | 5,744,000 | 5,559,000 | 3,122,000 | 1,634,000 | 4,768,000 | 1,932,000 | 1,752,000 | 7,612,000 | 1,049,000 | 2,700,000 | 119,698 |
| Group/Directors Accounts | 150,000 | |||||||||||
| other short term finances | ||||||||||||
| hp & lease commitments | ||||||||||||
| other current liabilities | 18,522,000 | 24,863,000 | 20,477,000 | 15,652,000 | 11,256,000 | 9,906,000 | 19,545,000 | 15,934,000 | 4,621,000 | 3,519,000 | 9,378,000 | 3,342,208 |
| total current liabilities | 23,076,000 | 30,607,000 | 26,036,000 | 18,774,000 | 12,890,000 | 14,674,000 | 21,477,000 | 17,686,000 | 12,233,000 | 4,568,000 | 12,078,000 | 3,461,906 |
| loans | ||||||||||||
| hp & lease commitments | ||||||||||||
| Accruals and Deferred Income | 1,688,000 | 1,576,000 | 1,108,000 | 599,000 | 522,000 | 517,000 | 337,000 | 341,000 | 329,000 | 152,000 | ||
| other liabilities | 16,500,000 | 10,000,000 | 16,500,000 | 16,500,000 | 6,500,000 | 6,500,000 | 2,600,000 | 6,500,000 | 6,500,000 | |||
| provisions | 20,118,000 | 20,329,000 | 19,949,000 | 13,617,000 | 10,295,000 | 8,689,000 | 7,316,000 | 6,715,000 | 3,197,000 | 1,889,000 | 1,772,000 | 43,879 |
| total long term liabilities | 38,306,000 | 31,905,000 | 37,557,000 | 30,716,000 | 17,317,000 | 15,706,000 | 7,653,000 | 9,656,000 | 10,026,000 | 8,541,000 | 1,772,000 | 43,879 |
| total liabilities | 61,382,000 | 62,512,000 | 63,593,000 | 49,490,000 | 30,207,000 | 30,380,000 | 29,130,000 | 27,342,000 | 22,259,000 | 13,109,000 | 13,850,000 | 3,505,785 |
| net assets | 74,204,000 | 81,013,000 | 78,677,000 | 72,212,000 | 51,539,000 | 47,209,000 | 39,392,000 | 34,487,000 | 14,359,000 | 7,693,000 | 7,157,000 | 204,342 |
| total shareholders funds | 74,204,000 | 81,013,000 | 78,677,000 | 72,212,000 | 51,539,000 | 47,209,000 | 39,392,000 | 34,487,000 | 14,359,000 | 7,693,000 | 7,157,000 | 204,342 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Profit | -7,127,000 | 3,484,000 | 13,882,000 | 25,432,000 | 5,944,000 | 8,910,000 | 5,444,000 | 24,041,000 | 8,031,000 | 665,000 | 8,705,000 | 266,565 |
| Depreciation | 10,604,000 | 8,642,000 | 6,801,000 | 6,055,000 | 4,187,000 | 4,290,000 | 2,168,000 | 1,868,000 | 1,617,000 | 1,310,000 | 16,000 | 3,740 |
| Amortisation | 690,000 | 809,000 | 1,025,000 | 754,000 | 409,000 | 56,000 | ||||||
| Tax | -312,000 | -1,154,000 | -7,432,000 | -4,764,000 | -1,568,000 | -1,035,000 | -1,105,000 | -3,790,000 | -1,291,000 | -147,000 | -1,752,000 | -62,223 |
| Stock | 1,092,000 | 1,247,000 | 6,000 | 55,000 | -52,000 | -14,000 | -41,000 | 107,000 | ||||
| Debtors | -3,032,000 | -1,202,000 | 8,733,000 | 4,075,000 | 795,000 | -1,708,000 | 167,000 | 488,000 | 6,692,000 | 186,000 | 4,200,739 | 3,069,261 |
| Creditors | -1,340,000 | 185,000 | 2,437,000 | 1,488,000 | -3,134,000 | 2,836,000 | 180,000 | -5,860,000 | 6,563,000 | -1,651,000 | 2,580,302 | 119,698 |
| Accruals and Deferred Income | -6,229,000 | 4,854,000 | 5,334,000 | 4,473,000 | 1,355,000 | -9,459,000 | 3,607,000 | 11,325,000 | 1,279,000 | -5,707,000 | 6,035,792 | 3,342,208 |
| Deferred Taxes & Provisions | -211,000 | 380,000 | 6,332,000 | 3,322,000 | 1,606,000 | 1,373,000 | 601,000 | 3,518,000 | 1,308,000 | 117,000 | 1,728,121 | 43,879 |
| Cash flow from operations | -1,985,000 | 17,155,000 | 19,640,000 | 32,630,000 | 8,004,000 | 8,679,000 | 10,780,000 | 30,628,000 | 10,856,000 | -5,706,000 | 13,112,476 | 644,606 |
| Investing Activities | ||||||||||||
| capital expenditure | -5,586,000 | -26,386,000 | ||||||||||
| Change in Investments | 150,000 | |||||||||||
| cash flow from investments | -150,000 | -5,586,000 | -26,386,000 | |||||||||
| Financing Activities | ||||||||||||
| Bank loans | ||||||||||||
| Group/Directors Accounts | 150,000 | |||||||||||
| Other Short Term Loans | ||||||||||||
| Long term loans | ||||||||||||
| Hire Purchase and Lease Commitments | ||||||||||||
| other long term liabilities | 6,500,000 | -6,500,000 | 10,000,000 | 6,500,000 | -2,600,000 | -3,900,000 | 6,500,000 | |||||
| share issue | ||||||||||||
| interest | 630,000 | 6,000 | 15,000 | 5,000 | -46,000 | -49,000 | -66,000 | -104,000 | -93,000 | 18,000 | ||
| cash flow from financing | 7,280,000 | -6,494,000 | 15,000 | 10,005,000 | -46,000 | 6,451,000 | -2,666,000 | -4,004,000 | -93,000 | 6,518,000 | -342 | |
| cash and cash equivalents | ||||||||||||
| cash | 1,551,000 | 502,000 | 4,631,000 | 17,552,000 | 182,000 | 1,959,000 | 2,256,000 | 1,166,000 | 2,309,000 | -1,122,000 | 4,376,354 | 392,646 |
| overdraft | ||||||||||||
| change in cash | 1,551,000 | 502,000 | 4,631,000 | 17,552,000 | 182,000 | 1,959,000 | 2,256,000 | 1,166,000 | 2,309,000 | -1,122,000 | 4,376,354 | 392,646 |
cell therapy catapult limited Credit Report and Business Information
Cell Therapy Catapult Limited Competitor Analysis
Perform a competitor analysis for cell therapy catapult limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other large companies, companies in SE1 area or any other competitors across 12 key performance metrics.
cell therapy catapult limited Ownership
CELL THERAPY CATAPULT LIMITED group structure
Cell Therapy Catapult Limited has 4 subsidiary companies.
Ultimate parent company
CELL THERAPY CATAPULT LIMITED
07964711
4 subsidiaries
cell therapy catapult limited directors
Cell Therapy Catapult Limited currently has 14 directors. The longest serving directors include Dr Steven Chatfield (Jan 2016) and Mr Matthew Durdy (Jan 2016).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Steven Chatfield | 68 years | Jan 2016 | - | Director | |
| Mr Matthew Durdy | 58 years | Jan 2016 | - | Director | |
| Dr Stephen Ward | 54 years | Jan 2016 | - | Director | |
| Mr Stuart Henderson | 66 years | Jun 2016 | - | Director | |
| Ms Jacqueline Barry | 59 years | Feb 2017 | - | Director | |
| Professor Sir Bruce Keogh | 70 years | Sep 2018 | - | Director | |
| Professor Uta Griesenbach | United Kingdom | 61 years | Sep 2018 | - | Director |
| Ms Hilary Newiss | 69 years | Sep 2018 | - | Director | |
| Prof Angela Thomas | England | 67 years | Oct 2020 | - | Director |
| Mr Ian McCubbin | 68 years | Feb 2022 | - | Director |
P&L
March 2024turnover
53.5m
-9%
operating profit
-7.1m
-305%
gross margin
98.6%
+0.97%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
74.2m
-0.08%
total assets
135.6m
-0.06%
cash
35.8m
+0.05%
net assets
Total assets minus all liabilities
cell therapy catapult limited company details
company number
07964711
Type
Private Ltd By Guarantee w/o Share Cap
industry
74909 - Other professional, scientific and technical activities (not including environmental consultancy or quantity surveying) n.e.c.
incorporation date
February 2012
age
13
incorporated
UK
ultimate parent company
accounts
Group
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
COOPER PARRY GROUP LIMITED
address
12th floor tower wing b, guys hospital, london, SE1 9RT
Bank
-
Legal Advisor
-
cell therapy catapult limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to cell therapy catapult limited. Currently there are 2 open charges and 0 have been satisfied in the past.
cell therapy catapult limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for CELL THERAPY CATAPULT LIMITED. This can take several minutes, an email will notify you when this has completed.
cell therapy catapult limited Companies House Filings - See Documents
| date | description | view/download |
|---|
